CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.2355
0.82%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0290
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

OPKO Health Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.2255
Open* 1.2455
1-Year Change* -18.96%
Day's Range* 1.2055 - 1.2555
52 wk Range 0.85-2.24
Average Volume (10 days) 44.38M
Average Volume (3 months) 183.05M
Market Cap 758.52M
P/E Ratio -100.00K
Shares Outstanding 773.06M
Revenue 866.93M
EPS -0.28
Dividend (Yield %) N/A
Beta 1.81
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2024 1.2355 0.0100 0.82% 1.2255 1.2555 1.2055
Apr 12, 2024 1.2255 -0.0200 -1.61% 1.2455 1.2555 1.2055
Apr 11, 2024 1.2755 0.0100 0.79% 1.2655 1.2755 1.2055
Apr 10, 2024 1.2555 -0.0500 -3.83% 1.3055 1.3255 1.2055
Apr 9, 2024 1.3755 -0.0100 -0.72% 1.3855 1.4155 1.3555
Apr 8, 2024 1.3855 0.0300 2.21% 1.3555 1.4155 1.3455
Apr 5, 2024 1.3455 0.0000 0.00% 1.3455 1.3555 1.3255
Apr 4, 2024 1.3555 0.0200 1.50% 1.3355 1.3855 1.3355
Apr 3, 2024 1.3355 0.0300 2.30% 1.3055 1.3855 1.3055
Apr 2, 2024 1.3455 0.1100 8.90% 1.2355 1.3555 1.2355
Apr 1, 2024 1.3055 0.1200 10.12% 1.1855 1.3455 1.1855
Mar 28, 2024 1.1855 0.0700 6.28% 1.1155 1.2355 1.1155
Mar 27, 2024 1.0555 0.0600 6.03% 0.9955 1.0955 0.9917
Mar 26, 2024 0.9955 0.0190 1.95% 0.9765 0.9955 0.9762
Mar 25, 2024 0.9955 0.0400 4.19% 0.9555 0.9955 0.9030
Mar 22, 2024 0.9555 -0.0127 -1.31% 0.9682 0.9823 0.9075
Mar 21, 2024 0.9137 0.0272 3.07% 0.8865 0.9868 0.8776
Mar 20, 2024 0.8734 0.0004 0.05% 0.8730 0.9190 0.8555
Mar 19, 2024 0.8717 0.0156 1.82% 0.8561 0.8770 0.8556
Mar 18, 2024 0.8656 -0.0288 -3.22% 0.8944 0.8977 0.8555

OPKO Health, Inc. Events

Time (UTC) Country Event
Wednesday, May 1, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 OPKO Health Inc Earnings Release
Q1 2024 OPKO Health Inc Earnings Release

Forecast

-

Previous

-
Friday, June 21, 2024

Time (UTC)

14:00

Country

US

Event

OPKO Health Inc Annual Shareholders Meeting
OPKO Health Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 1, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 OPKO Health Inc Earnings Release
Q2 2024 OPKO Health Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1004.2 1774.72 1435.41 901.935 990.266
Revenue 1004.2 1774.72 1435.41 901.935 990.266
Cost of Revenue, Total 715.977 1193.19 894.408 572.484 604.636
Gross Profit 288.219 581.524 541.005 329.451 385.63
Total Operating Expense 1230.45 1755.97 1377.7 1175.99 1161.46
Selling/General/Admin. Expenses, Total 372.672 468.857 354.573 340.305 353.446
Research & Development 73.887 76.85 75.316 117.87 125.586
Depreciation / Amortization 87.784 50.278 56.391 64.783 67.933
Unusual Expense (Income) -18.559 -31.508 1 95.399 26.678
Other Operating Expenses, Total -1.312 -1.703 -3.989 -14.854 -16.816
Operating Income -226.253 18.75 57.714 -274.052 -171.197
Interest Income (Expense), Net Non-Operating -9.426 -18.006 -21.732 -19.632 -7.607
Other, Net -155.842 -14.77 12.701 -11.281 1.535
Net Income Before Taxes -391.521 -14.026 48.683 -304.965 -177.269
Net Income After Taxes -328.022 -29.515 31.066 -312.025 -138.543
Equity In Affiliates -0.383 -0.629 -0.48 -2.9 -14.497
Net Income Before Extra. Items -328.405 -30.144 30.586 -314.925 -153.04
Net Income -328.405 -30.144 30.586 -314.925 -153.04
Income Available to Common Excl. Extra. Items -328.405 -30.143 30.586 -314.925 -153.04
Income Available to Common Incl. Extra. Items -328.405 -30.143 30.586 -314.925 -153.04
Diluted Net Income -328.405 -30.143 30.586 -314.925 -153.04
Diluted Weighted Average Shares 719.061 648.078 640.655 595.454 563.144
Diluted EPS Excluding Extraordinary Items -0.45671 -0.04651 0.04774 -0.52888 -0.27176
Diluted Normalized EPS -0.47349 -0.07811 0.04874 -0.42474 -0.24097
Total Extraordinary Items
Total Adjustments to Net Income 0.001
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 265.418 237.577 185.34 179.744 309.893
Revenue 265.418 237.577 185.34 179.744 309.893
Cost of Revenue, Total 138.939 138.314 129.346 148.445 194.311
Gross Profit 126.479 99.263 55.994 31.299 115.582
Total Operating Expense 258.393 268.171 240.609 267.564 320.632
Selling/General/Admin. Expenses, Total 79.794 75.642 73.997 79.674 101.464
Research & Development 18.159 32.605 19.528 18.792 17.254
Depreciation / Amortization 21.535 21.474 21.559 21.407 22.793
Other Operating Expenses, Total -0.034 0.136 -0.627 -0.754 0.175
Operating Income 7.025 -30.594 -55.269 -87.82 -10.739
Interest Income (Expense), Net Non-Operating -2.058 -3.42 -2.162 -1.904 -2.576
Other, Net -21.417 17.017 -44.751 -36.651 -72.997
Net Income Before Taxes -16.45 -16.997 -102.182 -126.375 -86.312
Net Income After Taxes -19.598 -18.23 -85.207 -86.048 -101.382
Equity In Affiliates -0.042 -0.037 -0.024 -0.043 -0.268
Net Income Before Extra. Items -19.64 -18.267 -85.231 -86.091 -101.65
Net Income -19.64 -18.267 -85.231 -86.091 -101.65
Income Available to Common Excl. Extra. Items -19.64 -18.267 -85.231 -86.091 -101.65
Income Available to Common Incl. Extra. Items -19.64 -18.267 -85.231 -86.091 -101.65
Diluted Net Income -19.64 -18.267 -85.231 -86.091 -101.65
Diluted Weighted Average Shares 751.727 751.506 751.878 750.396 712.549
Diluted EPS Excluding Extraordinary Items -0.02613 -0.02431 -0.11336 -0.11473 -0.14266
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.02613 -0.02431 -0.11612 -0.11473 -0.15667
Unusual Expense (Income) 0 -3.194 0 -15.365
Total Adjustments to Net Income
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 394.525 823.013 523.179 324.045 317.731
Cash and Short Term Investments 153.191 134.71 72.211 85.452 96.473
Cash & Equivalents 153.191 134.71 72.211 85.452 96.473
Total Receivables, Net 148.608 265.588 302.256 157.687 161.983
Accounts Receivable - Trade, Net 127.312 259.637 286.314 134.617 143.907
Total Inventory 74.06 86.502 132.341 53.434 42.299
Prepaid Expenses 12.414 15.024 11.062 11.633 13.129
Other Current Assets, Total 6.252 321.189 5.309 15.839 3.847
Total Assets 2167.26 2399.72 2473.06 2309.27 2451.07
Property/Plant/Equipment, Total - Net 121.604 123.955 178.289 166.491 144.674
Property/Plant/Equipment, Total - Gross 264.01 257.281 343.058 302.936 256.336
Accumulated Depreciation, Total -142.406 -133.326 -164.769 -136.445 -111.662
Goodwill, Net 595.851 520.601 680.602 671.94 700.193
Intangibles, Net 1018.52 911.883 1065.2 1119.16 1250.02
Long Term Investments 28.08 10.729 15.731 20.626 30.373
Other Long Term Assets, Total 8.679 9.534 10.06 7.008 8.077
Total Current Liabilities 213.48 330.008 375.483 249.119 288.321
Accounts Payable 66.993 82.04 100.883 62.537 47.395
Accrued Expenses 107.088 202.602 231.661 154.891 133.476
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 39.399 16.952 27.156 12.362 40.693
Other Current Liabilities, Total 0 28.414 15.783 19.329 66.757
Total Liabilities 605.611 714.589 801.512 694.513 659.781
Total Long Term Debt 226.558 193.083 228.631 263.909 172.771
Long Term Debt 219.469 190.159 225.826 259.863 167.151
Capital Lease Obligations 7.089 2.924 2.805 4.046 5.62
Deferred Income Tax 126.426 148.487 137.208 118.717 115.193
Other Liabilities, Total 39.147 43.011 60.19 62.768 83.496
Total Equity 1561.65 1685.13 1671.55 1614.76 1791.29
Common Stock 7.813 6.901 6.706 6.704 5.869
Additional Paid-In Capital 3421.87 3222.49 3152.69 3142.99 3004.42
Retained Earnings (Accumulated Deficit) -1822.92 -1511.98 -1481.83 -1511.08 -1197.08
Treasury Stock - Common -1.791 -1.791 -1.791 -1.791 -1.791
Unrealized Gain (Loss) 0
Other Equity, Total -43.323 -30.495 -4.225 -22.07 -20.131
Total Liabilities & Shareholders’ Equity 2167.26 2399.72 2473.06 2309.27 2451.07
Total Common Shares Outstanding 772.651 681.427 670.036 669.829 586.332
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 357.239 433.789 406.418 394.525 413.971
Cash and Short Term Investments 138.621 108.108 110.83 153.191 180.838
Cash & Equivalents 138.621 108.108 110.83 153.191 180.838
Total Receivables, Net 126.505 228.093 203.41 148.608 138.248
Accounts Receivable - Trade, Net 117.449 210.982 121.486 127.312 123.188
Total Inventory 68.96 73.749 75.411 74.06 71.429
Prepaid Expenses 16.15 16.628 10.686 12.414 17.116
Other Current Assets, Total 7.003 7.211 6.081 6.252 6.34
Total Assets 2056.68 2158.9 2169.67 2167.26 2224.78
Property/Plant/Equipment, Total - Net 122.86 113.814 117.685 121.604 119.739
Goodwill, Net 594.457 597.375 597.38 595.851 573.499
Intangibles, Net 953.414 977.195 998.616 1018.52 1030.14
Long Term Investments 19.377 27.783 41.231 28.08 77.804
Other Long Term Assets, Total 9.333 8.943 8.34 8.679 9.636
Total Current Liabilities 200.554 226.45 222.422 213.48 267.272
Accounts Payable 66.801 87.877 80.503 66.993 49.748
Accrued Expenses 96.984 107.035 114.58 107.088 120.713
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 33.049 31.538 27.339 39.399 96.554
Other Current Liabilities, Total 3.72 0 0.257
Total Liabilities 612.112 623.551 617.86 605.611 595.717
Total Long Term Debt 228.857 227.98 228.019 226.558 155.135
Long Term Debt 221.177 220.71 220.129 219.469 150.785
Capital Lease Obligations 7.68 7.27 7.89 7.089 4.35
Deferred Income Tax 138.007 133.049 129.668 126.426 135.073
Other Liabilities, Total 44.694 36.072 37.751 39.147 38.237
Total Equity 1444.57 1535.35 1551.81 1561.65 1629.07
Common Stock 7.817 7.817 7.813 7.813 7.814
Additional Paid-In Capital 3430.34 3427.09 3424.59 3421.87 3418.76
Retained Earnings (Accumulated Deficit) -1945.3 -1860.83 -1841.19 -1822.92 -1737.69
Treasury Stock - Common -1.791 -1.791 -1.791 -1.791 -1.791
Other Equity, Total -46.495 -36.942 -37.611 -43.323 -58.026
Total Liabilities & Shareholders’ Equity 2056.68 2158.9 2169.67 2167.26 2224.78
Total Common Shares Outstanding 773.057 773.038 772.651 772.651 772.686
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -328.405 -30.143 30.586 -314.925 -153.04
Cash From Operating Activities -95.189 38.337 39.476 -172.522 -109.141
Cash From Operating Activities 108.655 78.716 85.362 93.807 97.344
Deferred Taxes -74.405 10.159 15.64 4.324 -35.133
Non-Cash Items 156.312 0.087 5.497 113.079 39.832
Cash Taxes Paid 8.037 5.969 0.903 -2.667 1.41
Cash Interest Paid 7.42 8.515 10.908 11.873 2.076
Changes in Working Capital 42.654 -20.482 -97.609 -68.807 -58.144
Cash From Investing Activities 91.038 35.949 -18.327 -13.27 -26.119
Capital Expenditures -24.578 -32.156 -33.682 -12.741 -27.858
Other Investing Cash Flow Items, Total 115.616 68.105 15.355 -0.529 1.739
Cash From Financing Activities 22.971 -10.351 -35.076 175.248 140.909
Issuance (Retirement) of Stock, Net -0.774 1.08 0.756 276.352 148.673
Issuance (Retirement) of Debt, Net 23.745 -11.243 -35.832 -93.342 -7.764
Foreign Exchange Effects -0.339 -1.436 0.686 -0.477 -0.675
Net Change in Cash 18.481 62.499 -13.241 -11.021 4.974
Financing Cash Flow Items 0 -0.188 0 -7.762
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -18.267 -328.405 -243.174 -157.083 -55.433
Cash From Operating Activities -22.647 -95.189 -63.569 -31.333 -19.856
Cash From Operating Activities 26.446 108.655 82.195 55.809 27.814
Deferred Taxes 0.102 -74.405 -48.883 -8.942 -22.356
Non-Cash Items -1.421 156.312 105.856 72.125 9.879
Cash Taxes Paid 0.477 8.037 4.471 4.647 1.063
Cash Interest Paid 3.83 7.42 7.019 3.554 3.42
Changes in Working Capital -29.507 42.654 40.437 6.758 20.24
Cash From Investing Activities -7.717 91.038 98.91 103.592 -4.903
Capital Expenditures -3.037 -24.578 -18.242 -10.63 -5.251
Other Investing Cash Flow Items, Total -4.68 115.616 117.152 114.222 0.348
Cash From Financing Activities -13.119 22.971 12.827 4.383 -7.891
Issuance (Retirement) of Stock, Net 0 -0.774 -0.688 -0.224 0.136
Issuance (Retirement) of Debt, Net -13.119 23.745 13.515 4.607 -8.027
Foreign Exchange Effects 1.122 -0.339 -2.04 -0.894 0.221
Net Change in Cash -42.361 18.481 46.128 75.748 -32.429
Financing Cash Flow Items 0 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

OPKO Health, Inc. Company profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company''s Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Industry: Medical & Diagnostic Laboratories

4400 Biscayne Blvd.
MIAMI
FLORIDA 33137
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

US100

17,688.30 Price
-0.340% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

62,180.95 Price
-1.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,371.66 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.50

ETH/USD

3,021.03 Price
-1.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading